- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 109105, 14 pages
Induction of Apoptosis by Luteolin Involving Akt Inactivation in Human 786-O Renal Cell Carcinoma Cells
1Division of Urology, Taichung Veterans General Hospital, Taichung 407, Taiwan
2Department of Pharmacology, School of Medicine, Chung-Shan Medical University, Taichung 402, Taiwan
3Department of Education and Research, Taichung Veterans General Hospital, Taichung 407, Taiwan
4Center for General Education, Tunghai University, Taichung 407, Taiwan
5Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402, Taiwan
6Graduate School of Nursing, Hung-Kuang University, Taichung 433, Taiwan
Received 26 August 2012; Revised 23 December 2012; Accepted 2 January 2013
Academic Editor: Hong Q. Zhang
Copyright © 2013 Yen-Chuan Ou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. F. Birt, S. Hendrich, and W. Wang, “Dietary agents in cancer prevention: flavonoids and isoflavonoids,” Pharmacology and Therapeutics, vol. 90, no. 2-3, pp. 157–177, 2001.
- Y. Li, H. Fang, and W. Xu, “Recent advance in the research of flavonoids as anticancer agents,” Mini-Reviews in Medicinal Chemistry, vol. 7, no. 7, pp. 663–678, 2007.
- S. Ramos, “Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention,” The Journal of Nutritional Biochemistry, vol. 18, no. 7, pp. 427–442, 2007.
- H. J. Lee, C. J. Wang, H. C. Kuo, F. P. Chou, L. F. Jean, and T. H. Tseng, “Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK,” Toxicology and Applied Pharmacology, vol. 203, no. 2, pp. 124–131, 2005.
- A. C. Cheng, T. C. Huang, C. S. Lai et al., “Pyrrolidine dithiocarbamate inhibition of luteolin-induced apoptosis through up-regulated phosphorylation of akt and caspase-9 in human leukemia HL-60 cells,” Journal of Agricultural and Food Chemistry, vol. 54, no. 12, pp. 4215–4221, 2006.
- C. S. Ong, J. Zhou, C. N. Ong, and H. M. Shen, “Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt-GSK-3β-Cyclin D1 pathway,” Cancer Letters, vol. 298, no. 2, pp. 167–175, 2010.
- A. Y. Choi, J. H. Choi, H. Yoon et al., “Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells,” European Journal of Pharmacology, vol. 668, no. 1-2, pp. 115–126, 2011.
- Y. S. Lin, P. H. Tsai, C. C. Kandaswami et al., “Effects of dietary flavonoids, luteolin, and quercetin on the reversal of epithelial-mesenchymal transition in A431 epidermal cancer cells,” Cancer Science, vol. 102, no. 10, pp. 1829–1839, 2011.
- X. Tang, H. Wang, L. Fan et al., “Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs,” Free Radical Biology and Medicine, vol. 50, no. 11, pp. 1599–1609, 2011.
- L. Bai, X. Xu, Q. Wang et al., “A superoxide-mediated mitogen-activated protein kinase phosphatase-1 degradation and c-Jun NH2-terminal kinase activation pathway for luteolin-induced lung cancer cytotoxicity,” Molecular Pharmacology, vol. 81, no. 4, pp. 549–555, 2012.
- P. S. Rao, A. Satelli, M. Moridani, M. Jenkins, and U. S. Rao, “Luteolin induces apoptosis in multidrug resistant cancer cells without affecting the drug transporter function: involvement of cell line-specific apoptotic mechanisms,” International Journal of Cancer, vol. 130, no. 11, pp. 2703–2714, 2012.
- C. Coppin, F. Porzsolt, A. Awa, J. Kumpf, A. Coldman, and T. Wilt, “Immunotherapy for advanced renal cell cancer,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD001425, 2005.
- B. I. Rini, S. C. Campbell, and B. Escudier, “Renal cell carcinoma,” The Lancet, vol. 373, no. 9669, pp. 1119–1132, 2009.
- R. J. Motzer and R. M. Bukowski, “Targeted therapy for metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 24, no. 35, pp. 5601–5608, 2006.
- G. Hudes, M. Carducci, P. Tomczak et al., “Global ARCC Trial. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma,” The New England Journal of Medicine, vol. 356, no. 22, pp. 2271–2281, 2007.
- J. M. G. Larkin, T. R. Ferguson, L. M. Pickering et al., “A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma,” British Journal of Cancer, vol. 103, no. 8, pp. 1149–1153, 2010.
- M. E. Gore, S. Hariharan, C. Porta et al., “Sunitinib in metastatic renal cell carcinoma patients with brain metastases,” Cancer, vol. 117, no. 3, pp. 501–509, 2011.
- C. M. Huijts, S. J. Santegoets, A. J. van den Eertwegh et al., “Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer,” BMC Cancer, vol. 11, article 505, 2011.
- D. Roulin, L. Waselle, A. Dormond-Meuwly, M. Dufour, N. Demartines, and O. Dormond, “Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib,” Molecular Cancer, vol. 10, article 90, 2011.
- Z. Xia, M. Dickens, J. Raingeaud, R. J. Davis, and M. E. Greenberg, “Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis,” Science, vol. 270, no. 5240, pp. 1326–1331, 1995.
- T. P. Garrington and G. L. Johnson, “Organization and regulation of mitogen-activated protein kinase signaling pathways,” Current Opinion in Cell Biology, vol. 11, no. 2, pp. 211–218, 1999.
- R. Zhang, D. Luo, R. Miao et al., “Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis,” Oncogene, vol. 24, no. 24, pp. 3954–3963, 2005.
- Y. Takano, H. Iwata, Y. Yano et al., “Up-regulation of connexin 32 gene by 5-aza-2′-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling,” Biochemical Pharmacology, vol. 80, no. 4, pp. 463–470, 2010.
- M. Fujita, T. Yagami, M. Fujio et al., “Cytotoxicity of troglitazone through PPAR-independent pathway and p38 MAPK pathway in renal cell carcinoma,” Cancer Letters, vol. 312, no. 2, pp. 219–227, 2011.
- Y. C. Ou, C. R. Yang, C. L. Cheng, S. L. Raung, Y. Y. Hung, and C. J. Chen, “Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT,” European Journal of Pharmacology, vol. 563, no. 1–3, pp. 49–60, 2007.
- C. Y. Chang, C. C. Shen, H. L. Su, and C. J. Chen, “Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation,” Journal of Neurooncology, vol. 105, no. 3, pp. 507–522, 2011.
- A. H. Kim, G. Khursigara, X. Sun, T. F. Franke, and M. V. Chao, “Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1,” Molecular and Cellular Biology, vol. 21, no. 3, pp. 893–901, 2001.
- T. G. Choi, J. Lee, J. Ha, and S. S. Kim, “Apoptosis signal-regulating kinase 1 is an intracellular inducer of p38 MAPK-mediated myogenic signalling in cardiac myoblasts,” Biochimica et Biophysica Acta, vol. 1813, no. 8, pp. 1412–1421, 2011.
- R. Beck, J. Verrax, T. Gonze et al., “Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death,” Biochemical Pharmacology, vol. 77, no. 3, pp. 375–383, 2009.
- S. C. Shen, L. Y. Yang, H. Y. Lin, C. Y. Wu, T. H. Su, and Y. C. Chen, “Reactive oxygen species-dependent HSP90 protein cleavage participates in arsenical As+3- and MMA+3-induced apoptosis through inhibition of telomerase activity via JNK activation,” Toxicology and Applied Pharmacology, vol. 229, no. 2, pp. 239–251, 2008.
- H. Ichijo, E. Nishida, K. Irie et al., “Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways,” Science, vol. 275, no. 5296, pp. 90–94, 1997.
- J. Matsukawa, A. Matsuzawa, K. Takeda, and H. Ichijo, “The ASK1-MAP kinase cascades in mammalian stress response,” Journal of Biochemistry, vol. 136, no. 3, pp. 261–265, 2004.
- M. Hassan, O. Feyen, and E. Grinstein, “Fas-induced apoptosis of renal cell carcinoma is mediated by apoptosis signal-regulating kinase 1 via mitochondrial damage-dependent caspase-8 activation,” Cellular Oncology, vol. 31, no. 6, pp. 437–456, 2009.
- P. C. Ferriola, V. Cody, and E. Middleton, “Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships,” Biochemical Pharmacology, vol. 38, no. 10, pp. 1617–1624, 1989.
- L. Neckers, “Heat shock protein 90: the cancer chaperone,” Journal of Biosciences, vol. 32, no. 3, pp. 517–530, 2007.
- C. B. Clark, M. J. Rane, D. El Mehdi, C. J. Miller, L. R. Sachleben Jr., and E. Gozal, “Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex,” Free Radical Biology and Medicine, vol. 47, no. 10, pp. 1440–1449, 2009.
- A. Taiyab, A. S. Sreedhar, and C. M. Rao, “Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma,” Biochemical Pharmacology, vol. 78, no. 2, pp. 142–152, 2009.
- C. Sourbier, V. Lindner, H. Lang et al., “The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy,” Cancer Research, vol. 66, no. 10, pp. 5130–5142, 2006.
- T. K. Kao, Y. C. Ou, S. Y. Lin et al., “Luteolin inhibits cytokine expression in endotoxin/cytokine-stimulated microglia,” Journal of Nutritional Biochemistry, vol. 22, no. 7, pp. 612–624, 2011.
- S. W. Kim, H. J. Kim, Y. J. Chun, and M. Y. Kim, “Ceramide produces apoptosis through induction of p27kip1 by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells,” Journal of Toxicology and Environmental Health A, vol. 73, no. 21-22, pp. 1465–1476, 2010.
- D. R. Hostetter, C. R. K. Loeb, F. Chu, and C. S. Craik, “Hip is a pro-survival substrate of granzyme B,” Journal of Biological Chemistry, vol. 282, no. 38, pp. 27865–27874, 2007.
- H. Chen, Y. Xia, D. Fang, D. Hawke, and Z. Lu, “Caspase-10-mediated heat shock protein 90β cleavage promotes UVB irradiation-induced cell apoptosis,” Molecular and Cellular Biology, vol. 29, no. 13, pp. 3657–3664, 2009.
- V. A. Robb, M. Karbowniczek, A. J. Klein-Szanto, and E. P. Henske, “Activation of the mTOR signaling pathway in renal clear cell carcinoma,” Journal of Urology, vol. 177, no. 1, pp. 346–352, 2007.
- R. J. Motzer, B. Escudier, S. Oudard et al., “Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial,” The Lancet, vol. 372, no. 9637, pp. 449–456, 2008.
- D. C. Cho, M. B. Cohen, D. J. Panka et al., “The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma,” Clinical Cancer Research, vol. 16, no. 14, pp. 3628–3638, 2010.
- C. X. Xu, Y. Li, P. Yue et al., “The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo,” PLoS ONE, vol. 6, no. 6, Article ID e20899, 2011.
- M. R. Cardillo and F. Ippoliti, “Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma,” International Journal of Immunopathology and Pharmacology, vol. 20, no. 1, pp. 37–46, 2007.
- M. Hämäläinen, R. Nieminen, P. Vuorela, M. Heinonen, and E. Moilanen, “Anti-inflammatory effects of flavonoids: Genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-κB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-κB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages,” Mediators of Inflammation, vol. 2007, Article ID 45673, 2007.
- K. Shimoi, H. Okada, M. Furugori et al., “Intestinal absorption of luteolin and luteolin 7-O-β-glucoside in rats and humans,” FEBS Letters, vol. 438, no. 3, pp. 220–224, 1998.